Promising fungal drug trial halted early
Disease control
Terminated
This study tested a new drug called APX001 in 21 adults with serious mold infections that did not respond to standard treatments. The goal was to see if the drug could reduce deaths and control the infection. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated May 14, 2026 12:02 UTC